Pharmaceuticals company Alkem Laboratories announced Q1FY26 results Total Revenue from Operations was Rs 33,711 million, with YoY growth of 11.2%. EBITDA were Rs 7,391 million, resulting in an EBITDA margin of 21.9% vs 20.1% in Q1FY25, EBITDA grew by 21.4% YoY. Profit before tax before exceptional items was Rs 7,581 million, YoY growth of 22.4%. Net Profit (after Minority Interest) was Rs 6,643 million, YoY growth of 21.8%. R&D; expenses for Q1FY26 were Rs 1,184 million, or 3.5% of total revenue from operations, vs Rs 1,257 million in Q1FY25 at 4.1% of total revenue from operations. Vikas Gupta, CEO, Alkem, said: “Q1FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.” Result PDF